Pharmafile Logo
Pharmafocus logo
Advanced Search

Rheumatology

Showing 4 posts of 4 posts found.

Alvotech biosimilar receives EC marketing approval

November 26, 2025
Research and Development Alvotech, Immunology, Inflammatory disease, Rheumatology

The European Commission (EC) has granted marketing authorisation for Gobivaz, Alvotech’s first-in-market biosimilar of Simponi (golimumab), which is used for …

News

Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition

August 14, 2025
Medical Communications, Research and Development European Alliance of Associations for Rheumatology, European Medicines Agency, IgG4-related disease, Rheumatology, Sanofi

The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) inhibitor, rilzabrutinib, for the treatment …

News
lab

Bristol Myers Squibb reports positive results for psoriatic arthritis treatment

June 13, 2025
Medical Communications, Research and Development European Alliance of Associations for Rheumatology, Rheumatology, bristol myers squibb, clinical trial, psoriatic arthritis

Bristol Myers Squibb (BMS) has presented new data from its phase 3 POETYK PsA-1 trial, showing that Sotyktu (deucravacitinib) significantly …

News
Rheumatoid arthritis

Positive results announced for Levicept’s moderate-to-severe osteoarthritis treatment

August 6, 2024
Research and Development Levicept, Rheumatology, osteoarthritis, trial

Biotechnology company Levicept has announced positive results from its phase 2 trial into LEVI-04, for the treatment of osteoarthritis.

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026